Calithera Biosciences, Inc.
CALA · OTC
12/31/2022 | 12/31/2021 | 12/31/2020 | 12/31/2019 | |
|---|---|---|---|---|
| Revenue | $0 | $10 | $0 | $0 |
| % Growth | -100% | – | – | – |
| Cost of Goods Sold | $1 | $1 | $2 | $2 |
| Gross Profit | -$1 | $8 | -$2 | -$2 |
| % Margin | – | 85.3% | – | – |
| R&D Expenses | $29 | $103 | $71 | $76 |
| G&A Expenses | $14 | $21 | $20 | $17 |
| SG&A Expenses | $12 | $21 | $20 | $17 |
| Sales & Mktg Exp. | -$1 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | -$2 | -$2 | $0 |
| Operating Expenses | $41 | $123 | $90 | $93 |
| Operating Income | -$42 | -$114 | -$91 | -$93 |
| % Margin | – | -1,172.1% | – | – |
| Other Income/Exp. Net | $2 | -$1 | $1 | $3 |
| Pre-Tax Income | -$40 | -$115 | -$90 | -$90 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$19 | -$115 | -$89 | -$86 |
| % Margin | – | -1,180.4% | – | – |
| EPS | -7.94 | -31.16 | -26.2 | -36.5 |
| % Growth | 74.5% | -18.9% | 28.2% | – |
| EPS Diluted | -7.94 | -31.16 | -26.2 | -36.5 |
| Weighted Avg Shares Out | 5 | 4 | 3 | 2 |
| Weighted Avg Shares Out Dil | 5 | 4 | 3 | 2 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $1 | $3 |
| Interest Expense | $0 | $0 | $0 | $0 |
| Depreciation & Amortization | $1 | $1 | $2 | $2 |
| EBITDA | -$38 | -$114 | -$88 | -$88 |
| % Margin | – | -1,165.7% | – | – |